Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids
使用人扁桃体类器官研究对流感抗原的保护性适应性免疫反应
基本信息
- 批准号:10733719
- 负责人:
- 金额:$ 64.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAffectAgeAntibodiesAntibody AffinityAntibody DiversityAntibody ResponseAntigensAreaB-LymphocytesBloodBlood specimenCD4 Positive T LymphocytesCell CommunicationCell Differentiation processCell MaintenanceCellsChildhoodClinicalDataDisparateEmerging Communicable DiseasesFemaleFrequenciesFutureGoalsHelper-Inducer T-LymphocyteHumanHypertrophyImmuneImmune responseImmunityImmunologyIn VitroIndividualInfectionInfluenzaIntegration Host FactorsInvestigationKineticsKnowledgeLifeLymphoid TissueMediatingMedicineModalityMolecularMorbidity - disease rateMucous MembraneMutationNatureObstructive Sleep ApneaOrganoidsParticipantPatientsPhenotypePlasmaPopulationProductivityProtein ArrayRecording of previous eventsResearchRoleSeasonsSerologySignal PathwaySignal TransductionStructure of germinal center of lymph nodeSystemT cell responseT-Cell ActivationT-LymphocyteTechnologyTestingThromboplastinTissuesTonsilTonsillectomyVaccinationVaccine DesignVaccinesVariantVirusadaptive immune responseadaptive immunityage relatedantibody detectioncross reactivitydesignearly childhoodexperimental studyhuman modelin vivoin vivo evaluationinfluenza infectioninfluenza virus straininfluenza virus vaccineinsightmalemortalityneutralizing antibodynew technologynovelnovel vaccinespandemic potentialperipheral bloodrational designrecruitresponsesexuniversal influenza vaccinevaccination strategyvaccine developmentvaccine trial
项目摘要
PROJECT SUMMARY/ABSTRACT
Influenza virus infections cause significant global morbidity and mortality and pose a serious pandemic risk due
to the virus’s propensity for reassortment and mutation. Current influenza vaccines elicit strain-specific
responses and are only 10-60% effective depending on the year. There is an urgent need for a universal
influenza vaccine that elicits robust, persistent, and broadly cross-reactive B and T cell responses. Designing
such a vaccine will require a comprehensive understanding of how features from both the host and the antigen
modulate the magnitude, quality, and breadth of the influenza-specific response. Most human influenza studies
have been limited to peripheral blood sampling, even though the critical cellular decisions that lead to productive
adaptive immune responses occur within lymphoid tissues. Our long-term goal is to define the dynamics of the
lymphoid tissue microenvironment, including cell-cell interactions and signaling pathways, that elicit protective
immune responses in humans. Our central hypothesis is that immune signatures from mucosal lymphoid tissue
are significantly more informative than peripheral blood in developing immunization strategies that elicit robust
and broadly cross-reactive influenza responses. To address this question, we propose to leverage a high
throughput in vitro organoid platform derived from primary human tonsil tissues. Tonsils are considered both
lymphoid and mucosal tissues; they are also accessible from otherwise-healthy patients undergoing
tonsillectomy for hypertrophy or obstructive sleep apnea. Participants are demographically diverse and cover
the full human age span; males and females are represented at similar proportions. Immune organoids derived
from tonsils accurately model human germinal center responses, specific antibody secretion, and T cell activation
in response to influenza antigens. They are also able to capture host-mediated inter-individual immune variation
related to patient age, sex, and immune history. Furthermore, tonsil organoids can be used to track the kinetics
of the adaptive immune response and enable the mechanistic insights needed to rationally design a universal
influenza vaccine. The goal of this application is to understand how host features and influenza antigen features
contribute to both the magnitude and quality of the influenza immune response in humans. This proposal is
supported by strong preliminary data and if successful, will open new areas of investigation for universal influenza
vaccine development by identifying correlates and predictors of protection. We will combine comprehensive
phenotyping and mechanistic experimental approaches to define the key drivers within human lymphoid tissues
that lead to narrow, strain-specific responses. The novelty of this application lies in the systems immunology
approach that integrates demographic, serological, phenotypic, functional, and repertoire readouts in a well-
controlled immune organoid platform. Completion of the proposed experiments will help us rapidly identify
correlates of protection and guide the design and testing of a broadly cross-reactive universal influenza vaccine.
项目总结/摘要
流感病毒感染导致全球显著的发病率和死亡率,并构成严重的大流行风险,
病毒的重组和突变倾向目前的流感疫苗引起菌株特异性
反应和只有10-60%的有效性取决于一年。迫切需要一个普遍的
流感疫苗激发了稳健、持久和广泛交叉反应性B和T细胞应答。设计
这样的疫苗需要全面了解宿主和抗原的特性
调节流感特异性反应的幅度、质量和广度。大多数人类流感研究
一直局限于外周血采样,即使关键的细胞决定,导致生产
适应性免疫应答发生在淋巴组织内。我们的长期目标是定义
淋巴组织微环境,包括细胞-细胞相互作用和信号传导途径,
人类的免疫反应。我们的中心假设是粘膜淋巴组织的免疫信号
在制定免疫策略方面,
和广泛交叉反应的流感反应。为了解决这个问题,我们建议利用一个高
来源于原代人扁桃体组织的体外类器官平台的通量。扁桃体被认为是
淋巴和粘膜组织;它们也可以从其他健康的患者接受
扁桃体切除术治疗肥大或阻塞性睡眠呼吸暂停。参与者在人口统计学上是多样化的,
人类的整个年龄段;男性和女性的比例相似。免疫类器官衍生
从扁桃体中精确模拟人类生殖中心反应、特异性抗体分泌和T细胞活化
对流感抗原的反应。它们还能够捕获宿主介导的个体间免疫变异
与患者年龄、性别和免疫史有关。此外,扁桃体类器官可用于跟踪动力学
适应性免疫反应,并使合理设计一个通用的
流感疫苗。本应用程序的目标是了解宿主特征和流感抗原特征
有助于人类流感免疫应答的程度和质量。这项建议是
如果成功的话,将为普遍性流感开辟新的研究领域。
通过识别保护的相关因素和预测因素来开发疫苗。我们将联合收割机
确定人类淋巴组织内关键驱动因素的表型和机制实验方法
这导致了狭窄的、菌株特异性的反应。这种应用的新奇在于系统免疫学
一种将人口统计学、血清学、表型、功能和库读数整合在一起的方法,
受控免疫类器官平台。完成拟议的实验将有助于我们迅速确定
保护的相关性,并指导广泛交叉反应的通用流感疫苗的设计和测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisa Wagar其他文献
Lisa Wagar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 64.26万 - 项目类别:














{{item.name}}会员




